Day: June 16, 2022

The Group held a webinar focused on consumer-facing markets Brussels, June 16, 2022  Solvay held a webinar for the investment community on the Consumer businesses that will be part of the future SpecialtyCo. Today, this sector is represented mainly by Novecare and Aroma Performance businesses, which are currently included in the Solutions business segment. This webinar marked a continuation of Solvay’s series that began in December 2021 with an ESG update, followed by the materials supplied to the Automotive industry.   “Consumer” refers to a diverse group of businesses that touch all of us in our daily lives. These are markets driven by demand from consumers and regulators for sustainable and high-performing solutions. The majority of these activities are categorized into four main areas of focus for Solvay: Agrochemicals, Home...

OSLO, Norway, June 16, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that it has been uplisted to the main list of the Oslo Stock Exchange (OSE) with first day of trading today, June 16, 2022. Nykode Therapeutics had traded on the Euronext Growth trading platform in Oslo since October 2020. “Today, Nykode reached a significant inflection point, signaling our growth as a leading member of the biotech industry in Europe. Nykode’s uplisting to the main list of the Oslo Stock Exchange enables us to reach a broader base of global institutional investors, increase liquidity of the Company’s shares, and better showcase our value proposition as a leading immunotherapy...

Clermont-Ferrand, June 16, 2022 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Four-for-one stock split of Michelin shares on June 16, 2022 As announced in the press release published on May 16, 2022, Michelin’s four-for-one stock split is effective today, June 16, 2022. It has resulted in the delisting of 178,530,462 existing shares and the listing of 714,121,848 new shares to replace them on Euronext under the new ISIN code FR001400AJ45 (the ML ticker symbol remains unchanged). This transaction has no impact on the double voting rights attached to the shares under the conditions set out in the Company’s Bylaws. It does not incur any costs or formalities for Michelin’s shareholders and does not impact their rights in any way. Yves Chapot, General Manager and Chief Financial Officer of Michelin, said: “The stock split...

INVL Partner Global Infrastructure Fund I, established by the leading asset management company INVL Asset Management, has raised an additional USD 7.965 million to invest in the infrastructure fund of a world-class asset manager with 26 years of experience. Twenty-five investors joined the Fund in the second placement of units. In total, the Fund has already raised USD 37.495 million from a total of 89 investors. The Fund’s units are distributed by INVL Family Office.  “The anxiety in capital markets continues unabated, both because of the war in Ukraine and because of the slowing economic growth and further inflationary pressures. In such an environment, investors are looking for new ways to diversify their funds and to protect them from depreciation. The results of the placement show that Baltic investors are successfully...

OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.This collaboration will give OSE the opportunity to further develop its digital tools and infrastructures, particularly in terms of Artificial Intelligence and algorithmic approaches applied to the development of innovative first-in-class immunotherapies.NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups. This program was launched during the 6th edition of “Viva Technology”, the most important Startup and Tech event organized in Europe...

SAMPO PLC                 STOCK EXCHANGE RELEASE         16/06/2022 at 08:30 am Sampo plc’s share buybacks 15/06/2022 On 15/06/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  16,388 41.55 AQEU  25,067 41.65 CEUX  10,768 41.67 TQEX  87,777 41.61 XHELTOTAL 140,000 41.62  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...

Maranello (Italy), June 16, 2022 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) will host today its Capital Markets Day in Maranello (Italy). A live webcast will be available on the Company’s corporate website, commencing today at 9:00 a.m. BST / 10:00 a.m. CEST / 4:00 a.m. EDT. The webcast details and the presentation delivered during the event will be available in the Investors section of the Ferrari corporate website (https://www.ferrari.com/en-EN/corporate/capital-markets-day-2022). For those unable to participate in the live session, a replay will remain archived on the corporate website.AttachmentFNV CMD 2022 Time PR 16.6.22 ENG

Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints Initial data will be presented at the Alzheimer’s Association International Conference (AAIC) on August 2, 2022 LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow...